Pornpimol Rianthavorn1, Athitaya Buddhasri2. 1. Division of Nephrology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 1873 King Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand. Pornpimol.R@chula.ac.th. 2. Division of Nephrology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 1873 King Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand.
Abstract
BACKGROUND: Data on global (IV-G) and segmental (IV-S) diffuse proliferative lupus nephritis (DPLN) in children are lacking. METHODS: To determine the clinicopathology and prognosis of DPLN subclasses IV-G and IV-S, we analyzed the clinical, laboratory, and demographic data of 56 children aged <18 years diagnosed with DPLN [36 (64.3%) with IV-G; 20 (35.7%) with IV-S] between 2004 and 2013. Clinical endpoints were: (1) complete remission (CR), (2) chronic kidney disease [CKD; defined as estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m(2) or end-stage renal disease (ESRD)], and (3) death. RESULTS: Proteinuria and the activity index were higher in patients with IV-G (p < 0.05). Global endocapillary proliferation and leukocyte exudation were predominant in IV-G patients, whereas segmental endocapillary proliferation was predominant in patients with IV-S (p < 0.005). CR rates in IV-G and IV-S patients were 50 and 60%, respectively (p = 0.47). Renal survival rates, defined as an eGFR of ≥60 mL/min/1.73 m(2), were 93, 78, and 64% at 1, 5, and 10 years, respectively. Patient survival rates at 1, 5, and 10 years were 98, 96, and 91%, respectively. Patient and renal survival rates were similar in both subclasses. CONCLUSIONS: Although patients with IV-G and IV-S displayed some clinical and histopathological disparities, renal outcomes were similar. The majority of children with DPLN reached adulthood but accrued significant renal damage. Treatment regimens which can slow the progression of CKD are needed.
BACKGROUND: Data on global (IV-G) and segmental (IV-S) diffuse proliferative lupus nephritis (DPLN) in children are lacking. METHODS: To determine the clinicopathology and prognosis of DPLN subclasses IV-G and IV-S, we analyzed the clinical, laboratory, and demographic data of 56 children aged <18 years diagnosed with DPLN [36 (64.3%) with IV-G; 20 (35.7%) with IV-S] between 2004 and 2013. Clinical endpoints were: (1) complete remission (CR), (2) chronic kidney disease [CKD; defined as estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m(2) or end-stage renal disease (ESRD)], and (3) death. RESULTS:Proteinuria and the activity index were higher in patients with IV-G (p < 0.05). Global endocapillary proliferation and leukocyte exudation were predominant in IV-G patients, whereas segmental endocapillary proliferation was predominant in patients with IV-S (p < 0.005). CR rates in IV-G and IV-S patients were 50 and 60%, respectively (p = 0.47). Renal survival rates, defined as an eGFR of ≥60 mL/min/1.73 m(2), were 93, 78, and 64% at 1, 5, and 10 years, respectively. Patient survival rates at 1, 5, and 10 years were 98, 96, and 91%, respectively. Patient and renal survival rates were similar in both subclasses. CONCLUSIONS: Although patients with IV-G and IV-S displayed some clinical and histopathological disparities, renal outcomes were similar. The majority of children with DPLN reached adulthood but accrued significant renal damage. Treatment regimens which can slow the progression of CKD are needed.
Authors: V A H Sato; I D B Marques; P T Goldenstein; L P F Carmo; L B Jorge; S M O Titan; R T Barros; V Woronik Journal: Lupus Date: 2012-03-26 Impact factor: 2.911
Authors: Ronald J Hogg; Susan Furth; Kevin V Lemley; Ronald Portman; George J Schwartz; Josef Coresh; Ethan Balk; Joseph Lau; Adeera Levin; Annamaria T Kausz; Garabed Eknoyan; Andrew S Levey Journal: Pediatrics Date: 2003-06 Impact factor: 7.124
Authors: F E Mackie; G Kainer; N Adib; C Boros; E J Elliott; R Fahy; J Munro; K Murray; A Rosenberg; B Wainstein; J B Ziegler; D Singh-Grewal Journal: Lupus Date: 2014-10-06 Impact factor: 2.911
Authors: Jessica L Turnier; Hermine I Brunner; Michael Bennett; Ashwaq Aleed; Gaurav Gulati; Wendy D Haffey; Sherry Thornton; Michael Wagner; Prasad Devarajan; David Witte; Kenneth D Greis; Bruce Aronow Journal: Rheumatology (Oxford) Date: 2019-02-01 Impact factor: 7.580
Authors: Hermine I Brunner; Michael R Bennett; Gaurav Gulati; Khalid Abulaban; Marisa S Klein-Gitelman; Stacy P Ardoin; Lori B Tucker; Kelly A Rouster-Stevens; David Witte; Jun Ying; Prasad Devarajan Journal: J Rheumatol Date: 2017-06-15 Impact factor: 4.666
Authors: Scott E Wenderfer; Joyce C Chang; Amy Goodwin Davies; Ingrid Y Luna; Rebecca Scobell; Cora Sears; Bliss Magella; Mark Mitsnefes; Brian R Stotter; Vikas R Dharnidharka; Katherine D Nowicki; Bradley P Dixon; Megan Kelton; Joseph T Flynn; Caroline Gluck; Mahmoud Kallash; William E Smoyer; Andrea Knight; Sangeeta Sule; Hanieh Razzaghi; L Charles Bailey; Susan L Furth; Christopher B Forrest; Michelle R Denburg; Meredith A Atkinson Journal: Clin J Am Soc Nephrol Date: 2021-11-03 Impact factor: 8.237
Authors: Jessica L Turnier; Ndate Fall; Sherry Thornton; David Witte; Michael R Bennett; Simone Appenzeller; Marisa S Klein-Gitelman; Alexei A Grom; Hermine I Brunner Journal: Arthritis Res Ther Date: 2017-10-24 Impact factor: 5.156